Page last updated: 2024-09-03

y 27632 and Prostatic Neoplasms, Castration-Resistant

y 27632 has been researched along with Prostatic Neoplasms, Castration-Resistant in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bai, Y; Chen, X; Cheng, L; Feng, F; Han, T; Huang, C; Kong, Y; Li, C; Liu, J; Liu, X; Wang, R; Zhang, Z	1

Other Studies

1 other study(ies) available for y 27632 and Prostatic Neoplasms, Castration-Resistant

Article	Year
Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. The Prostate, 2020, Volume: 80, Issue:3 Topics: Amides; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Random Allocation; Receptors, Androgen; rho-Associated Kinases; Wnt Signaling Pathway; Xenograft Model Antitumor Assays	2020

Article

Year

Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.

The Prostate, 2020, Volume: 80, Issue:3

Topics: Amides; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Random Allocation; Receptors, Androgen; rho-Associated Kinases; Wnt Signaling Pathway; Xenograft Model Antitumor Assays

2020